G Tsvetov1, I Shimon, C Benbassat. 1. Endocrine Institute, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel 49100.
Abstract
UNLABELLED: Adrenal incidentaloma (AI) is frequently found in patients with a history of malignancy and, as such, is not always considered a true incidental finding. OBJECTIVE: To compare the short-term clinical and biochemical behavior of adrenal incidentalomas between oncology and non-oncology patients. DESIGN: Retrospective comparative case series of 100 consecutive patients with adrenal incidentaloma, followed from 1995 to 2005 in the endocrinology clinic of a tertiary university medical center. MAIN OUTCOME: A history of malignancy was present in 32 patients. Median follow-up was 24 months. Mean tumor size was 24+/-10 mm. Endocrine evaluation yielded functional abnormalities in 12.2% (subclinical Cushing's 7.4%, Cushing's syndrome 1.1%, hyperaldosteronism 1.3%, pheochromocytoma 3.6%). During follow-up, adrenal function remained unchanged in all patients, but tumor growth was seen in 12.5%. Compared to the non-oncology patients, the oncology group had a higher mean age (67.5+/-9.6 vs 59.4+/-1.3 yr, p=0.001) and greater tumor growth (23.3% vs 7%, p=0.035), with no significant differences for tumor size, functional abnormalities, and extent of change in tumor size. Surgery was performed in 9 patients (3 oncologic) and revealed metastasis in one. None of the other patients had clinical or radiological findings suggesting adrenal malignancy. CONCLUSION: Our study suggests a similar clinical behavior of adrenal incidentaloma in oncology and non-oncology patients. More studies are needed to assist clinicians in selecting oncology patients with AI for whom a more conservative approach can be recommended.
UNLABELLED: Adrenal incidentaloma (AI) is frequently found in patients with a history of malignancy and, as such, is not always considered a true incidental finding. OBJECTIVE: To compare the short-term clinical and biochemical behavior of adrenal incidentalomas between oncology and non-oncology patients. DESIGN: Retrospective comparative case series of 100 consecutive patients with adrenal incidentaloma, followed from 1995 to 2005 in the endocrinology clinic of a tertiary university medical center. MAIN OUTCOME: A history of malignancy was present in 32 patients. Median follow-up was 24 months. Mean tumor size was 24+/-10 mm. Endocrine evaluation yielded functional abnormalities in 12.2% (subclinical Cushing's 7.4%, Cushing's syndrome 1.1%, hyperaldosteronism 1.3%, pheochromocytoma 3.6%). During follow-up, adrenal function remained unchanged in all patients, but tumor growth was seen in 12.5%. Compared to the non-oncology patients, the oncology group had a higher mean age (67.5+/-9.6 vs 59.4+/-1.3 yr, p=0.001) and greater tumor growth (23.3% vs 7%, p=0.035), with no significant differences for tumor size, functional abnormalities, and extent of change in tumor size. Surgery was performed in 9 patients (3 oncologic) and revealed metastasis in one. None of the other patients had clinical or radiological findings suggesting adrenal malignancy. CONCLUSION: Our study suggests a similar clinical behavior of adrenal incidentaloma in oncology and non-oncology patients. More studies are needed to assist clinicians in selecting oncology patients with AI for whom a more conservative approach can be recommended.
Authors: M G Harisinghani; M M Maher; P F Hahn; D A Gervais; K Jhaveri; J Varghese; P R Mueller Journal: Clin Radiol Date: 2002-10 Impact factor: 2.350
Authors: Andrea Frilling; Karsten Tecklenborg; Frank Weber; Hilmar Kühl; Stephan Müller; Georgios Stamatis; Christoph Broelsch Journal: Surgery Date: 2004-12 Impact factor: 3.982
Authors: F Mantero; M Terzolo; G Arnaldi; G Osella; A M Masini; A Alì; M Giovagnetti; G Opocher; A Angeli Journal: J Clin Endocrinol Metab Date: 2000-02 Impact factor: 5.958
Authors: Melvin M Grumbach; Beverly M K Biller; Glenn D Braunstein; Karen K Campbell; J Aidan Carney; Paul A Godley; Emily L Harris; Joseph K T Lee; Yolanda C Oertel; Mitchell C Posner; Janet A Schlechte; H Samuel Wieand Journal: Ann Intern Med Date: 2003-03-04 Impact factor: 25.391
Authors: G Tirabassi; B Kola; M Ferretti; R Papa; T Mancini; F Mantero; M Scarpelli; M Boscaro; G Arnaldi Journal: J Endocrinol Invest Date: 2011-10-04 Impact factor: 4.256
Authors: S Grozinsky-Glasberg; A Szalat; C A Benbassat; A Gorshtein; R Weinstein; D Hirsch; I Shraga-Slutzky; G Tsvetov; D J Gross; I Shimon Journal: J Endocrinol Invest Date: 2010-05-17 Impact factor: 4.256
Authors: Mark Sherlock; Andrew Scarsbrook; Afroze Abbas; Sheila Fraser; Padiporn Limumpornpetch; Rosemary Dineen; Paul M Stewart Journal: Endocr Rev Date: 2020-12-01 Impact factor: 19.871